🇺🇸 FDA
Company

COGNITION

COGNITION THERAPEUTICS INC

CGTX biotech USA

Quick answer

COGNITION is a biotech company (CGTX) headquartered in PURCHASE, NY, USA with 24 tracked pipeline programs.

Pipeline (24)

project

CBD 100 mg/mL Oral Solution

Treatment Resistant Psychosis

Phase 3 · small_molecule · active

1 trials project

CBD 100 mg/mL Oral Solution

Psychosis

Phase 3 · small_molecule · active

1 trials project

Vortioxetine

Major Depressive Disorder

Phase 3 · small_molecule · completed

1 trials project

Active Comparator CT1812

Age-Related Macular Degeneration

Phase 2 · small_molecule · terminated

1 trials project

Active Treatment- CT1812 100 mg

Alzheimer Disease

Phase 2 · small_molecule · completed

1 trials project

Autobiographical Memory Flexibility (MemFlex) training

Major Depressive Disorder

Phase 2 · other · completed

1 trials project

C105

Cognition Disorders

Phase 2 · small_molecule · completed

1 trials project

CT1812

Early Alzheimer's Disease

Phase 2 · small_molecule · active

1 trials project

CT1812

Dementia With Lewy Bodies

Phase 2 · small_molecule · completed

1 trials project

CT1812

Mild to Moderate Alzheimer's Disease

Phase 2 · small_molecule · completed

1 trials project

CT1812

Alzheimer Disease

Phase 2 · small_molecule · completed

3 trials project

CT1812

Alzheimer's Disease

Phase 2 · small_molecule · completed

1 trials project

Dexmedetomidine

Alzheimer Disease

Phase 2 · small_molecule · completed

1 trials project

Memory Flexibility Training

Major Depressive Disorder

Phase 2 · other · completed

1 trials project

Oxytocin nasal spray

Oxidative Stress

Phase 2 · small_molecule · completed

1 trials project

Oxytocin nasal spray

Cold Exposure

Phase 2 · small_molecule · completed

1 trials project

Psilocybin

Treatment Resistant Depression

Phase 2 · small_molecule · completed

1 trials project

The Modular Protocol for Mental Health

Major Depressive Disorder

Phase 2 · other · completed

1 trials project

Vortioxetine

Post-COVID-19 Condition

Phase 2 · small_molecule · completed

1 trials project

golexanolone

Primary Biliary Cholangitis (PBC)

Phase 2 · small_molecule · active

1 trials project

300 mg [C14] CT1812

Alzheimer Disease

Phase 1 · small_molecule · completed

1 trials project

CT1812

Healthy Volunteers

Phase 1 · small_molecule · completed

1 trials project

CT1812

Cognitive Impairment

Phase 1 · small_molecule · completed

1 trials project

Itraconazole

Drug Interaction

Phase 1 · small_molecule · completed

1 trials

Drugs (1)

drug

benzgalantamine gluconate

ZUNVEYL

Patents (8)

patent

US 12208167

Coated tablets for pH-dependent release of benzgalantamine

Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12157743

Solid forms of Alpha-1062 gluconate

Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11795176

Solid forms of Alpha-1062 gluconate

Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11123351

Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxi

Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10603326

Pharmaceutical formulation of 3α-ethynyl-3β-hydroxyandrostan-17-one oxime

Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10351589

3.alpha.-ethynyl, 3.beta.-hydroxy-5.alpha.-pregnan-20-oxime for use in the treat

Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10342804

Steroid compound for use in the treatment of hepatic encephalopathy

Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10278977

Methods for treating hypersomnolence

Expires Mon May 02 2039 00:00:00 GMT+0000 (Coordinated Universal Time)